The Non-Malignant Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Revolutionary approaches for thalassemia
Thalassemia is caused by defects in either α or β globin chains, which are required for formation of functional hemoglobin molecules. Maria Domenica Cappellini, MD, of the University of Milan-Foundation IRCCS Policlinico Hospital, Milan, Italy, spoke to us at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about new treatments that seek to re-establish the balance between α and β chains to reduce ineffective erythropoiesis. Techniques for achieving these aims include: genome editing to increase production of fetal hemoglobin; correcting ineffective erythropoiesis using ACE inhibitors; and gene therapy.
